Australia markets open in 7 hours 42 minutes

Graphite Bio, Inc. (GRPH)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.82-0.05 (-0.56%)
At close: 04:00PM EST
8.82 0.00 (0.00%)
After hours: 06:03PM EST
Full screen
Trade prices are not sourced from all markets
Previous close8.87
Open8.75
Bid7.50 x 900
Ask10.08 x 1800
Day's range8.58 - 9.20
52-week range8.11 - 34.00
Volume148,987
Avg. volume276,795
Market cap512.257M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease

    SOUTH SAN FRANCISCO, Calif., November 17, 2021--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that the first patient has been enrolled in the company’s Phase 1/2 clinical trial of GPH101, an investigational gene-edited autologous hematopoietic stem cell therapy designed to directly correct the genetic mutation that causes sickle cell disease (

  • Business Wire

    Graphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results

    SOUTH SAN FRANCISCO, Calif., November 10, 2021--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today reported recent business progress and third quarter 2021 financial results.

  • Business Wire

    Graphite Bio Announces Presentation on Phase 1/2 CEDAR Trial of GPH101 in Sickle Cell Disease at Upcoming 63rd ASH Annual Meeting and Exposition

    SOUTH SAN FRANCISCO, Calif., November 04, 2021--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that information about the company’s Phase 1/2 CEDAR trial of GPH101, an investigational therapy designed to directly correct the genetic mutation that causes sickle cell disease (SCD), will be presented during a poster session at the 63rd American So